- Home
- NSPR
NSPR
InspireMD Inc.
as 12-18-2024 10:40am EST
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
| Founded: | 2005 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 63.0M | IPO Year: | N/A |
| Target Price: | $4.75 | AVG Volume (30 days): | 78.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $3.42 | Next Earning Date: | 11-12-2024 |
| Revenue: | $6,821,000 | Revenue Growth: | 24.70% |
| Revenue Growth (this year): | 13.31% | Revenue Growth (next year): | 52.91% |
Latest InspireMD Inc. News
NSPR Breaking Stock News: Dive into NSPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
GlobeNewswire
9 days ago
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
GlobeNewswire
23 days ago
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
Simply Wall St.
a month ago
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)
GuruFocus.com
a month ago
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...
GlobeNewswire
a month ago
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
a month ago
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings
GlobeNewswire
a month ago
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare NSPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NSPR InspireMD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.